 Stealth BioTherapeutics NASDAQ:MITO was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Friday, Zacks.com reports. The brokerage presently has a 1.50 price objective on the stock. Zacks Investment Researchs price objective would suggest a potential upside of 13.64 from the stocks current price. According ... 